376 results on '"Mürdter, Thomas"'
Search Results
2. Toward model-informed precision dosing for tamoxifen: A population-pharmacokinetic model with a continuous CYP2D6 activity scale
3. Assessing human urinary clomiphene metabolites after consumption of eggs from clomiphene-treated laying hens using chromatographic-mass spectrometric approaches
4. A human ex vivo coculture model to investigate peritoneal metastasis and innovative treatment options
5. Stereoselective quantification of phase 1 and 2 metabolites of clomiphene in human plasma and urine
6. Nonlinear Mixed‐Effects Model of Z‐Endoxifen Concentrations in Tamoxifen‐Treated Patients from the CEPAM Cohort.
7. Optimized protocol for metabolomic and lipidomic profiling in formalin-fixed paraffin-embedded kidney tissue by LC-MS
8. Stress-induced TRAILR2 expression overcomes TRAIL resistance in cancer cell spheroids
9. Protocol for establishing a coculture with fibroblasts and colorectal cancer organoids
10. The formation of estrogen-like tamoxifen metabolites and their influence on enzyme activity and gene expression of ADME genes
11. Identification and synthesis of (Z)‐3′‐hydroxy clomiphene as a new potential doping‐relevant metabolite of clomiphene
12. Toward model-informed precision dosing for tamoxifen:A population-pharmacokinetic model with a continuous CYP2D6 activity scale
13. Data from Triple Targeting of HER Receptors Overcomes Heregulin-mediated Resistance to EGFR Blockade in Colorectal Cancer
14. Supplementary Figure from Triple Targeting of HER Receptors Overcomes Heregulin-mediated Resistance to EGFR Blockade in Colorectal Cancer
15. Performance comparison of narrow-bore and capillary liquid-chromatography for non-targeted metabolomics profiling by HILIC-QTOF-MS
16. Data from Hyperthermia Synergizes with Chemotherapy by Inhibiting PARP1-Dependent DNA Replication Arrest
17. Supplementary Figures 1-8 from Hyperthermia Synergizes with Chemotherapy by Inhibiting PARP1-Dependent DNA Replication Arrest
18. Data from Cancer Cells Cue the p53 Response of Cancer-Associated Fibroblasts to Cisplatin
19. Supplementary Figure from Cancer Cells Cue the p53 Response of Cancer-Associated Fibroblasts to Cisplatin
20. Supplementary Figure Legends from Hyperthermia Synergizes with Chemotherapy by Inhibiting PARP1-Dependent DNA Replication Arrest
21. Supplementary Methods from Hyperthermia Synergizes with Chemotherapy by Inhibiting PARP1-Dependent DNA Replication Arrest
22. Supplementary Table 2 from Cancer Cells Cue the p53 Response of Cancer-Associated Fibroblasts to Cisplatin
23. Perfusion Air Culture of Precision-Cut Tumor Slices: An Ex Vivo System to Evaluate Individual Drug Response under Controlled Culture Conditions
24. Cross‐Ancestry Genome‐Wide Association Study Defines the Extended CYP2D6 Locus as the Principal Genetic Determinant of Endoxifen Plasma Concentrations
25. Prediction of Drug–Drug–Gene Interaction Scenarios of (E)-Clomiphene and Its Metabolites Using Physiologically Based Pharmacokinetic Modeling
26. A Temperature of 40 °C Appears to be a Critical Threshold for Potentiating Cytotoxic Chemotherapy In Vitro and in Peritoneal Carcinomatosis Patients Undergoing HIPEC
27. Quantitative bile acid profiling by liquid chromatography quadrupole time-of-flight mass spectrometry: monitoring hepatitis B therapy by a novel Na+-taurocholate cotransporting polypeptide inhibitor
28. Highly sensitive simultaneous quantification of estrogenic tamoxifen metabolites and steroid hormones by LC-MS/MS
29. Physiologically Based Pharmacokinetic Modeling to Describe the CYP2D6 Activity Score-Dependent Metabolism of Paroxetine, Atomoxetine and Risperidone
30. Pharmacologic Targeting of MMP2/9 Decreases Peritoneal Metastasis Formation of Colorectal Cancer in a Human Ex Vivo Peritoneum Culture Model
31. (Z)-Endoxifen and Early Recurrence of Breast Cancer: An Explorative Analysis in a Prospective Brazilian Study
32. Concomitant use of tamoxifen and endoxifen in postmenopausal early breast cancer: prediction of plasma levels by physiologically-based pharmacokinetic modeling
33. Nanoparticle mediated delivery of 2′-O-methyl-RNA leads to efficient telomerase inhibition and telomere shortening in human lung cancer cells
34. Triple Targeting of HER Receptors Overcomes Heregulin-mediated Resistance to EGFR Blockade in Colorectal Cancer
35. Abstract P1-07-08: Endoxifen predicts early recurrence in breast cancer: A Brazilian prospective study
36. TAMOXIFEN ADJUVANT INTERFERERS STUDY (TAIS STUDY): AN EXPLORATIVE ANALYSIS OF (Z)- ENDOXIFEN AND EARLY RECURRENCE OF BREAST CANCER IN A PROSPECTIVE BRAZILIAN STUDY
37. Efficient Telomerase Inhibition in Human Non-small Cell Lung Cancer Cells by Liposomal Delivery of 2′-O-Methyl-RNA
38. Intraperitoneal Chemotherapy of Peritoneal Carcinomatosis Using Pressurized Aerosol as an Alternative to Liquid Solution: First Evidence for Efficacy
39. Raman Imaging and Fluorescence Lifetime Imaging Microscopy for Diagnosis of Cancer State and Metabolic Monitoring
40. Simultaneous quantitative analysis of letrozole, its carbinol metabolite, and carbinol glucuronide in human plasma by LC-MS/MS
41. Quantification of clomiphene metabolite isomers in human plasma by rapid-resolution liquid chromatography–electrospray ionization–tandem mass spectrometry
42. Simulation with cells in vitro of tamoxifen treatment in premenopausal breast cancer patients with different CYP2D6 genotypes
43. Simulation-Based Assessment of the Impact of Non-Adherence on Endoxifen Target Attainment in Different Tamoxifen Dosing Strategies
44. TGFβ2 and TβRII are valid molecular biomarkers for the antiproliferative effects of tamoxifen and tamoxifen metabolites in breast cancer cells
45. Role of P-Glycoprotein Inhibition for Drug Interactions: Evidence from In Vitro and Pharmacoepidemiological Studies
46. Increased Absorption of Digoxin from the Human Jejunum Due to Inhibition of Intestinal Transporter-Mediated Efflux
47. Unchanged serum levels of advanced glycation endproducts in patients with liver disease
48. Computational Treatment Simulations to Assess the Need for Personalized Tamoxifen Dosing in Breast Cancer Patients of Different Biogeographical Groups
49. Population pharmacokinetics of oral busulfan in children
50. Influence of Age and Cytochrome P450 2C9 Genotype on the Steady-State Disposition of Diclofenac and Celecoxib
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.